» Articles » PMID: 35884169

Evolutionary Dynamics Between Phages and Bacteria As a Possible Approach for Designing Effective Phage Therapies Against Antibiotic-Resistant Bacteria

Overview
Specialty Pharmacology
Date 2022 Jul 27
PMID 35884169
Authors
Affiliations
Soon will be listed here.
Abstract

With the increasing global threat of antibiotic resistance, there is an urgent need to develop new effective therapies to tackle antibiotic-resistant bacterial infections. Bacteriophage therapy is considered as a possible alternative over antibiotics to treat antibiotic-resistant bacteria. However, bacteria can evolve resistance towards bacteriophages through antiphage defense mechanisms, which is a major limitation of phage therapy. The antiphage mechanisms target the phage life cycle, including adsorption, the injection of DNA, synthesis, the assembly of phage particles, and the release of progeny virions. The non-specific bacterial defense mechanisms include adsorption inhibition, superinfection exclusion, restriction-modification, and abortive infection systems. The antiphage defense mechanism includes a clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated (Cas) system. At the same time, phages can execute a counterstrategy against antiphage defense mechanisms. However, the antibiotic susceptibility and antibiotic resistance in bacteriophage-resistant bacteria still remain unclear in terms of evolutionary trade-offs and trade-ups between phages and bacteria. Since phage resistance has been a major barrier in phage therapy, the trade-offs can be a possible approach to design effective bacteriophage-mediated intervention strategies. Specifically, the trade-offs between phage resistance and antibiotic resistance can be used as therapeutic models for promoting antibiotic susceptibility and reducing virulence traits, known as bacteriophage steering or evolutionary medicine. Therefore, this review highlights the synergistic application of bacteriophages and antibiotics in association with the pleiotropic trade-offs of bacteriophage resistance.

Citing Articles

Addressing the global challenge of bacterial drug resistance: insights, strategies, and future directions.

Karnwal A, Jassim A, Mohammed A, Al-Tawaha A, Selvaraj M, Malik T Front Microbiol. 2025; 16:1517772.

PMID: 40066274 PMC: 11891257. DOI: 10.3389/fmicb.2025.1517772.


Isolation and characterization of fMGyn-Pae01, a phiKZ-like jumbo phage infecting Pseudomonas aeruginosa.

Ranta K, Skurnik M, Kiljunen S Virol J. 2025; 22(1):55.

PMID: 40033410 PMC: 11877940. DOI: 10.1186/s12985-025-02679-w.


Phage therapy could be key to conquering persistent bacterial lung infections in children.

Sithu Shein A, Hongsing P, Khatib A, Phattharapornjaroen P, Miyanaga K, Cui L NPJ Antimicrob Resist. 2025; 2(1):31.

PMID: 39843534 PMC: 11721074. DOI: 10.1038/s44259-024-00045-4.


The Combination of Phage Therapy and β-Lactam Antibiotics for the Effective Treatment of Infections.

Moryl M, Szychowska P, Dziag J, Rozalski A, Torzewska A Int J Mol Sci. 2025; 26(1.

PMID: 39795870 PMC: 11719584. DOI: 10.3390/ijms26010011.


Advancing Phage Therapy: A Comprehensive Review of the Safety, Efficacy, and Future Prospects for the Targeted Treatment of Bacterial Infections.

Palma M, Qi B Infect Dis Rep. 2024; 16(6):1127-1181.

PMID: 39728014 PMC: 11675988. DOI: 10.3390/idr16060092.


References
1.
Molineux I, SCHMITT C, Condreay J . Mutants of bacteriophage T7 that escape F restriction. J Mol Biol. 1989; 207(3):563-74. DOI: 10.1016/0022-2836(89)90465-8. View

2.
Moldovan R, Chapman-McQuiston E, Wu X . On kinetics of phage adsorption. Biophys J. 2007; 93(1):303-15. PMC: 1914437. DOI: 10.1529/biophysj.106.102962. View

3.
Nachega J, Chaisson R . Tuberculosis drug resistance: a global threat. Clin Infect Dis. 2003; 36(Suppl 1):S24-30. DOI: 10.1086/344657. View

4.
Slavcev R, Hayes S . Stationary phase-like properties of the bacteriophage lambda Rex exclusion phenotype. Mol Genet Genomics. 2003; 269(1):40-8. DOI: 10.1007/s00438-002-0787-x. View

5.
Rice C, Kelly S, OBrien S, Melaugh E, Ganacias J, Chai Z . Novel Phage-Derived Depolymerase with Activity against Biofilms. Microorganisms. 2021; 9(10). PMC: 8539402. DOI: 10.3390/microorganisms9102172. View